Cargando…
Selective modulator of nuclear receptor PPARγ with reduced adipogenic potential ameliorates experimental nephrotic syndrome
Glomerular disease manifests as nephrotic syndrome (NS) with high proteinuria and comorbidities, and is frequently refractory to standard treatments. We hypothesized that a selective modulator of PPARγ, GQ-16, will provide therapeutic advantage over traditional PPARγ agonists for NS treatment. We de...
Autores principales: | Bryant, Claire, Rask, Galen, Waller, Amanda P., Webb, Amy, Galdino-Pitta, Marina R., Amato, Angelica A., Cianciolo, Rachel, Govindarajan, Rajgopal, Becknell, Brian, Kerlin, Bryce A., Neves, Francisco A.R., Fornoni, Alessia, Agrawal, Shipra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927998/ https://www.ncbi.nlm.nih.gov/pubmed/35310946 http://dx.doi.org/10.1016/j.isci.2022.104001 |
Ejemplares similares
-
Adriamycin-Induced Nephropathy is Robust in N and Modest in J Substrain of C57BL/6
por: Bryant, Claire, et al.
Publicado: (2022) -
Alternatively Spliced Landscape of PPARγ mRNA in Podocytes Is Distinct from Adipose Tissue
por: Bryant, Claire, et al.
Publicado: (2022) -
Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome
por: Agrawal, Shipra, et al.
Publicado: (2021) -
Nephrotic syndrome‐associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors
por: Waller, Amanda P., et al.
Publicado: (2020) -
Honokiol: A non-adipogenic PPARγ agonist from nature()
por: Atanasov, Atanas G., et al.
Publicado: (2013)